How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Helicobacter Pylori Tester Without Endoscopy Market
- By Test Type: Urea Breath Test, Stool Antigen Test, Serology Test, Rapid Urease Test
- By End User: Hospitals, Diagnostic Laboratories, Clinics, Ambulatory Surgical Centers
- By Technology: Non-invasive Breath Analysis, Immunoassay, Molecular Diagnostic Techniques
- By Sample Type: Breath Sample, Stool Sample, Blood Sample
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Urea Breath Test leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 265 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.160 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.168 →
Full report · locked preview
Everything inside the Helicobacter Pylori Tester Without Endoscopy Market report
A complete, evidence-based study - 11 chapters and 111 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Test Type 4
End User 4
Technology 3
Sample Type 3
Companies profiled
Abbott Laboratories
Roche Diagnostics
Siemens Healthineers
bioMérieux
Thermo Fisher Scientific
Fujirebio
Hain Lifescience
Arkray
Alere (now part of Abbott)
Quidel Corporation
Sekisui Medical
Wondfo Biotech
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →bioMérieux
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Fujirebio
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Hain Lifescience
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Arkray
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Alere (now part of Abbott)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Quidel Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sekisui Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Wondfo Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Creative Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Zhejiang Orient Gene Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,500M by 2033 · 5.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Urea Breath Test43.8
- Stool Antigen Test17.2
- Serology Test18.5
- Rapid Urease Test20.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$322.1M → $534.9M · 6.5%
Europe$224.5M → $380.0M · 6.8%
Asia Pacific$204.9M → $294.7M · 4.6%
Latin America$126.9M → $194.6M · 5.5%
Middle East and Africa$97.6M → $138.0M · 4.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.472026
5.492027
5.502028
5.522029
5.522030
5.542031
5.542032
5.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories17.1
- Roche Diagnostics19.5
- Siemens Healthineers5.9
- bioMérieux10.0
- Thermo Fisher Scientific6.9
- Fujirebio12.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type18.2%
End User25.1%
Technology30.2%
Sample Type26.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe24.6
- Asia Pacific19.1
- Latin America12.6
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 79 | 76 | 97 | 94 | 96 | 95 | 90 |
| Roche Diagnostics | 78 | 71 | 69 | 91 | 84 | 82 | 79 |
| Siemens Healthineers | 68 | 87 | 84 | 86 | 78 | 76 | 80 |
| bioMérieux | 70 | 69 | 66 | 68 | 63 | 68 | 67 |
| Thermo Fisher Scientific | 69 | 55 | 51 | 54 | 55 | 74 | 60 |
| Fujirebio | 59 | 56 | 58 | 46 | 70 | 67 | 59 |
| Hain Lifescience | 62 | 60 | 43 | 43 | 65 | 57 | 55 |
| Arkray | 52 | 52 | 47 | 49 | 41 | 45 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Roche Diagnostics | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Siemens Healthineers | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| bioMérieux | ✓ | ✓ | ◐ | − | − | − |
| Thermo Fisher Scientific | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Fujirebio | ◐ | ◐ | − | − | ◐ | − |
| Hain Lifescience | − | − | ◐ | − | ✓ | ◐ |
| Arkray | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories90
2Siemens Healthineers80
3Roche Diagnostics79
4bioMérieux67
5Thermo Fisher Scientific60
6Fujirebio59
7Hain Lifescience55
8Arkray48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Abbott LaboratoriesRoche DiagnosticsSiemens Healthineers
Challenger1
Strong scale, closing on the leaders.
bioMérieux
Contender2
Focused players with pockets of strength.
Thermo Fisher ScientificFujirebio
Niche2
Specialists in a single segment or region.
Hain LifescienceArkray
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Helicobacter Pylori Tester Without Endoscopy Market — a $686M beachhead inside a $10.6B market.
Beachhead (SOM)$686Mobtainable near-term
Serviceable (SAM)$4.07Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Urea Breath Test
Best fit — highest urgency & budget in Test Type.
Economic buyer81 fit
Stool Antigen Test
Strong fit — clear ROI and a fast path to value.
End user70 fit
Serology Test
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Helicobacter Pylori Tester Without Endoscopy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation13%
Closed-won8%
$15.8KCAC
$92KLTV
5.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Helicobacter Pylori Tester Without Endoscopy Market is a resilient opportunity — $3.34B by 2033, compounding at 5.5%.
TAM · 2025$2.18Btoday
TAM · 2033$3.34Bforecast
CAGR5.5%2027–2033
Cumulative$24.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.34BTotal addressable market
SAM$1.14BServiceable available market
SOM$243MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.5% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.34BLarge & growingTAM by 2033 at 5.5% CAGR
$1.14BServiceable nowreachable with today’s model
$243MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.61BBear3.6% CAGR
$3.34BBase5.5% CAGR
$4.28BBull7.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Helicobacter Pylori Tester Without Endoscopy Market — a $4.00B market by 2033. Plan: grow share from 6.0% to 12.1%.
Market size · 2033$4.00Btotal addressable
Market CAGR7.0%2027–2033
Target share12.1%from 6.0% today
Revenue ambition$485Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.0% | 12.1% | Behind |
| Revenue | $248M | $485M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.9% | 42.4% | On track |
| Customer retention | 91.2% | 95.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $49M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Helicobacter Pylori Tester Without Endoscopy Market conversation — a $4.19B market you can size, segment and defend in minutes.
Market size · 2033$4.19Btotal opportunity
Growth9.0%CAGR to 2033
Addressable buyers1,470+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 2 mopayback period
$56K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Abbott LaboratoriesRoche DiagnosticsSiemens HealthineersbioMérieuxThermo Fisher ScientificFujirebioHain LifescienceArkray+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Helicobacter Pylori Tester Without Endoscopy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Helicobacter Pylori Tester Without Endoscopy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Non animal Type Hard Capsules Market
Market size, share, segmentation and regional forecast.
$575M market · 2025 base year
View reportMerkel Cell Carcinoma Treatment Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportDental Forceps Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportDental Drill Bits Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportMenopausal Hot Flashes Drugs Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportTardive Dyskinesia TD Treatment Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportAntidiabetic Sulphonylureas Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAkabane Vaccines Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportVeterinary Anthrax Vaccines Market
Market size, share, segmentation and regional forecast.
$486M market · 2025 base year
View reportMedical Intravenous Infusion Pump Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportEtoposide Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportEnoxolone Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.